1-9 of 9
for the German CML Study Group
Close
Sort by
Journal Articles

Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV

Susanne Saussele, MD, Michael Lauseker, Ulrike Proetel, MD, Martin C. Müller, MD, Benjamin Hanfstein, MD, Annette Schreiber, MD, Florian Nolte, MD, Gabriela M. Baerlocher, MD, Gerhard Ehninger, MD, Dominik Heim, MD, Dieter K. Hossfeld, MD, PhD, Stefan W. Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Joerg E. A. Schubert, MD, Hermann Einsele, MD, Matthias Hänel, MD, Anthony D. Ho, MD, PhD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Karsten Spiekermann, MD, Wolf Karsten Hofmann, MD, PhD, Jörg Hasford, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, MD, Rüdiger Hehlmann, MD, for The SAKK, for The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 781.
https://doi.org/10.1182/blood.V118.21.781.781
Published: 2011
Journal Articles

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

Benjamin Hanfstein, MD, Martin C. Müller, MD, Philipp Erben, MD, Michael Lauseker, Susanne Saussele, MD, Ulrike Proetel, MD, Susanne Schnittger, PhD, Claudia Haferlach, MD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Jörg E. A. Schubert, MD, Hermann Einsele, MD, Mathias Hänel, MD, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, for The SAKK, for The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 783.
https://doi.org/10.1182/blood.V118.21.783.783
Published: 2011
Journal Articles

Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV,

Benjamin Hanfstein, MD, Philipp Erben, MD, Susanne Saussele, MD, Michael Lauseker, Ulrike Proetel, MD, Sven Haag, Susanne Schnittger, PhD, Claudia Haferlach, MD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Jörg E. A. Schubert, MD, Hermann Einsele, MD, Mathias Hänel, MD, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD, for The German CML Study Group, for The SAKK
Journal: Blood
Blood (2011) 118 (21): 3773.
https://doi.org/10.1182/blood.V118.21.3773.3773
Published: 2011
Journal Articles

Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment

Martin C. Müller, MD, Benjamin Hanfstein, MD, Michael Lauseker, Philipp Erben, MD, Ulrike Proetel, MD, Susanne Schnittger, PhD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Joerg E. A. Schubert, MD, Hermann Einsele, MD, Matthias Hänel, MD, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Susanne Saussele, MD, Andreas Hochhaus, MD, for The SAKK, for The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 1681.
https://doi.org/10.1182/blood.V118.21.1681.1681
Published: 2011
Journal Articles

Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV

Martin C. Müller, MD, Andreas Hochhaus, MD, Michael Lauseker, Susanne Jung-Munkwitz, MD, Markus Pfirrmann, PhD, Armin Leitner, MD, Stefan W. Krause, MD, Nadine Pletsch, MD, Benjamin Hanfstein, MD, Susanne Schnittger, PhD, Alois Gratwohl, MD, Jörg Hasford, MD, Susanne Saussele, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 669.
https://doi.org/10.1182/blood.V116.21.669.669
Published: 2010
Journal Articles

Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV.

Susanne Saussele, MD, Nadine Pletsch, MD, Michael Lauseker, Armin Leitner, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Martin C. Müller, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Stefan W. Krause, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Anthony D. Ho, MD, FRCPC, Christiane Falge, MD, Matthias Hänel, MD, M. Pfreundschuh, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, MD, Karsten Spiekermann, MD, Steffen Koschmieder, MD, Cornelius F. Waller, MD, Martin Bentz, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, Jörg Hasford, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 3411.
https://doi.org/10.1182/blood.V116.21.3411.3411
Published: 2010
Journal Articles

Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV

Rüdiger Hehlmann, MD, Susanne Jung-Munkwitz, MD, Michael Lauseker, Martin C. Müller, MD, Armin Leitner, MD, Nadine Pletsch, MD, Ulrike Proetel, MD, Alois Gratwohl, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Christiane Falge, MD, Anthony D. Ho, MD, FRCPC, Matthias Hänel, MD, Michael Pfreundschuh, MD, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, CA, MD, Karsten Spiekermann, MD, Steffen Koschmieder, Cornelius F. Waller, MD, Martin Bentz, MD, Stefan W. Krause, MD, Benjamin Hanfstein, MD, Susanne Schnittger, PhD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Andreas Hochhaus, Susanne Saussele, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 357.
https://doi.org/10.1182/blood.V116.21.357.357
Published: 2010
Journal Articles

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

Clinical Trials & Observations
Susanne Saussele, Michael Lauseker, Alois Gratwohl, Dietrich W. Beelen, Donald Bunjes, Rainer Schwerdtfeger, Hans-Jochem Kolb, Anthony D. Ho, Christiane Falge, Ernst Holler, Günter Schlimok, Axel R. Zander, Renate Arnold, Lothar Kanz, Robert Dengler, Claudia Haferlach, Brigitte Schlegelberger, Markus Pfirrmann, Martin C. Müller, Susanne Schnittger, Armin Leitner, Nadine Pletsch, Andreas Hochhaus, Joerg Hasford, Rüdiger Hehlmann, for the German CML Study Group
Journal: Blood
Blood (2010) 115 (10): 1880–1885.
https://doi.org/10.1182/blood-2009-08-237115
Published: 2010
Includes: Supplemental data
Journal Articles

Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation.

Joerg Hasford, Michael Lauseker, Insa Gathmann, Markus Pfirrmann, PhD, Richard A. Larson, MD, François Guilhot, Stephen G O’Brien, Brian J. Druker, Ruediger Hehlmann, Andreas Hochhaus, MD, For the IRIS Study Group, For the German CML Study Group
Journal: Blood
Blood (2008) 112 (11): 2123.
https://doi.org/10.1182/blood.V112.11.2123.2123
Published: 2008